Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide in bone metastatic CRPC
NCT01091103Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2010
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in castration-resistant prostate cancer (CRPC), sponsored by Pfizer. Primary endpoints: Change From Baseline in Bone Marrow Testosterone at 9 weeks and Change From Baseline in Bone Marrow Dihydrotestosterone at 9 weeks. Started Feb 2010; status: completed.
02
Drugs
enzalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT01091103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01091103.